Olema Pharmaceuticals Inc (OLMA) News

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6...

Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

Data published in Molecular Cancer Therapeutics describes the scientific background underlying the design...

Form 4 - Statement of changes in beneficial ownership of securities

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, March 04, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”...

Form 144 - Report of proposed sale of securities

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Olema Oncology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”...